Advertisement
Screener

WAVE LIFE SCIENCES LTD. (WVE) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

WAVE LIFE SCIENCES LTD. Comprehensive Income

WAVE LIFE SCIENCES LTD. (WVE) reported Comprehensive Income of -$69.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-07-30

  • WAVE LIFE SCIENCES LTD. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$69.27M.
  • WAVE LIFE SCIENCES LTD. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$26.09M.
  • WAVE LIFE SCIENCES LTD. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$53.24M, a 282.64% decline year-over-year.
  • WAVE LIFE SCIENCES LTD. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$53.88M.
  • WAVE LIFE SCIENCES LTD. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$204.37M.
  • WAVE LIFE SCIENCES LTD. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$97.15M.
  • WAVE LIFE SCIENCES LTD. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$57.61M.
  • WAVE LIFE SCIENCES LTD. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$162.03M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed
2026-06-30-$69.27M
10-Q · filed 2026-07-30
-$95.36M
10-Q · filed 2026-07-30
-$148.60M
derived: sum of 3 quarters · filed 2026-07-30
-$202.48M
derived: sum of 4 quarters · filed 2026-07-30
2026-03-31-$26.09M
10-Q · filed 2026-04-28
-$79.33M
derived: sum of 2 quarters · filed 2026-04-28
-$133.21M
derived: sum of 3 quarters · filed 2026-04-28
-$183.64M
derived: sum of 4 quarters · filed 2026-07-30
2025-12-31-$53.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$107.12M
derived: sum of 2 quarters · filed 2026-02-26
-$157.55M
derived: sum of 3 quarters · filed 2026-07-30
-$204.37M
10-K · filed 2026-02-26
2025-09-30-$53.88M
10-Q · filed 2025-11-10
-$104.31M
derived: sum of 2 quarters · filed 2026-07-30
-$151.13M
10-Q · filed 2025-11-10
-$121.98M
derived: sum of 4 quarters · filed 2026-07-30
2025-06-30-$50.43M
10-Q · filed 2026-07-30
-$97.25M
10-Q · filed 2026-07-30
-$68.10M
derived: sum of 3 quarters · filed 2026-07-30
-$129.76M
derived: sum of 4 quarters · filed 2026-07-30
2025-03-31-$46.82M
10-Q · filed 2026-04-28
-$17.67M
derived: sum of 2 quarters · filed 2026-04-28
-$79.33M
derived: sum of 3 quarters · filed 2026-04-28
-$112.33M
derived: sum of 4 quarters · filed 2026-04-28
2024-12-31$29.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$32.51M
derived: sum of 2 quarters · filed 2026-02-26
-$65.51M
derived: sum of 3 quarters · filed 2026-02-26
-$97.15M
10-K · filed 2026-02-26
2024-09-30-$61.66M
10-Q · filed 2025-11-10
-$94.66M
derived: sum of 2 quarters · filed 2025-11-10
-$126.30M
10-Q · filed 2025-11-10
-$142.49M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30-$33.00M
10-Q · filed 2025-07-30
-$64.64M
10-Q · filed 2025-07-30
-$80.83M
derived: sum of 3 quarters · filed 2026-02-26
-$73.61M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$31.63M
10-Q · filed 2025-05-08
-$47.83M
derived: sum of 2 quarters · filed 2026-02-26
-$40.61M
derived: sum of 3 quarters · filed 2026-02-26
-$61.81M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31-$16.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$8.98M
derived: sum of 2 quarters · filed 2026-02-26
-$30.18M
derived: sum of 3 quarters · filed 2026-02-26
-$57.61M
10-K · filed 2026-02-26
2023-09-30$7.22M
10-Q · filed 2024-11-12
-$13.98M
derived: sum of 2 quarters · filed 2024-11-12
-$41.41M
10-Q · filed 2024-11-12
-$85.03M
derived: sum of 4 quarters · filed 2025-03-04
2023-06-30-$21.20M
10-Q · filed 2024-08-08
-$48.63M
10-Q · filed 2024-08-08
-$92.25M
derived: sum of 3 quarters · filed 2025-03-04
-$131.32M
derived: sum of 4 quarters · filed 2025-03-04
2023-03-31-$27.43M
10-Q · filed 2024-05-10
-$71.04M
derived: sum of 2 quarters · filed 2025-03-04
-$110.12M
derived: sum of 3 quarters · filed 2025-03-04
-$151.56M
derived: sum of 4 quarters · filed 2025-03-04
2022-12-31-$43.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04
-$82.69M
derived: sum of 2 quarters · filed 2025-03-04
-$124.13M
derived: sum of 3 quarters · filed 2025-03-04
-$162.03M
10-K · filed 2025-03-04
2022-09-30-$39.08M
10-Q · filed 2023-11-09
-$80.52M
derived: sum of 2 quarters · filed 2023-11-09
-$118.42M
10-Q · filed 2023-11-09
-$153.28M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30-$41.44M
10-Q · filed 2023-08-03
-$79.34M
10-Q · filed 2023-08-03
-$114.20M
derived: sum of 3 quarters · filed 2023-08-03
-$120.44M
derived: sum of 4 quarters · filed 2023-08-03
2022-03-31-$37.90M
10-Q · filed 2023-05-03
-$72.76M
derived: sum of 2 quarters · filed 2023-05-03
-$79.00M
derived: sum of 3 quarters · filed 2023-05-03
-$117.77M
derived: sum of 4 quarters · filed 2023-05-03
2021-12-31-$34.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23
-$41.10M
derived: sum of 2 quarters · filed 2023-03-23
-$79.87M
derived: sum of 3 quarters · filed 2023-03-23
-$122.45M
10-K · filed 2023-03-23
2021-09-30-$6.24M
10-Q · filed 2022-11-10
-$45.01M
derived: sum of 2 quarters · filed 2022-11-10
-$87.59M
10-Q · filed 2022-11-10
-$116.29M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30-$38.77M
10-Q · filed 2022-08-11
-$81.35M
10-Q · filed 2022-08-11
-$110.05M
derived: sum of 3 quarters · filed 2022-08-11
-$143.13M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31-$42.58M
10-Q · filed 2022-05-12
-$71.28M
derived: sum of 2 quarters · filed 2022-05-12
-$104.36M
derived: sum of 3 quarters · filed 2022-05-12
-$144.88M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31-$28.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03
-$61.78M
derived: sum of 2 quarters · filed 2022-03-03
-$102.30M
derived: sum of 3 quarters · filed 2022-03-03
-$149.79M
10-K · filed 2022-03-03
2020-09-30-$33.08M
10-Q · filed 2021-11-10
-$73.60M
derived: sum of 2 quarters · filed 2021-11-10
-$121.09M
10-Q · filed 2021-11-10
-$177.87M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30-$40.52M
10-Q · filed 2021-08-05
-$88.01M
10-Q · filed 2021-08-05
-$144.79M
derived: sum of 3 quarters · filed 2021-08-05
-$195.52M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31-$47.49M
10-Q · filed 2021-05-13
-$104.27M
derived: sum of 2 quarters · filed 2021-05-13
-$155.00M
derived: sum of 3 quarters · filed 2021-05-13
-$196.91M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31-$56.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04
-$107.51M
derived: sum of 2 quarters · filed 2021-03-04
-$149.42M
derived: sum of 3 quarters · filed 2021-03-04
-$193.52M
10-K · filed 2021-03-04
2019-09-30-$50.72M
10-Q · filed 2020-11-09
-$92.64M
derived: sum of 2 quarters · filed 2020-11-09
-$136.74M
10-Q · filed 2020-11-09
-$174.65M
derived: sum of 4 quarters · filed 2020-11-09
2019-06-30-$41.91M
10-Q · filed 2020-08-10
-$86.02M
10-Q · filed 2020-08-10
-$123.93M
derived: sum of 3 quarters · filed 2020-08-10
-$161.58M
derived: sum of 4 quarters · filed 2020-08-10
2019-03-31-$44.10M
10-Q · filed 2020-05-11
-$82.02M
derived: sum of 2 quarters · filed 2020-05-11
-$119.67M
derived: sum of 3 quarters · filed 2020-05-11
-$155.53M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31-$37.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
-$75.57M
derived: sum of 2 quarters · filed 2020-03-02
-$111.42M
derived: sum of 3 quarters · filed 2020-03-02
-$146.62M
10-K · filed 2020-03-02
2018-09-30-$37.65M
10-Q · filed 2019-11-05
-$73.51M
derived: sum of 2 quarters · filed 2019-11-05
-$108.70M
10-Q · filed 2019-11-05
-$139.11M
derived: sum of 4 quarters · filed 2020-03-02
2018-06-30-$35.86M
10-Q · filed 2019-08-06
-$71.05M
10-Q · filed 2019-08-06
-$101.45M
derived: sum of 3 quarters · filed 2020-03-02
-$126.95M
derived: sum of 4 quarters · filed 2020-03-02
2018-03-31-$35.19M
10-Q · filed 2019-05-10
-$65.60M
derived: sum of 2 quarters · filed 2020-03-02
-$91.09M
derived: sum of 3 quarters · filed 2020-03-02
-$115.68M
derived: sum of 4 quarters · filed 2020-03-02
2017-12-31-$30.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
-$55.90M
derived: sum of 2 quarters · filed 2020-03-02
-$80.49M
derived: sum of 3 quarters · filed 2020-03-02
-$101.57M
10-K · filed 2020-03-02
-$101.63M
10-K · filed 2018-03-12
2017-09-30-$25.49M
10-Q · filed 2018-11-09
-$26.13M
10-Q · filed 2017-11-09
-$50.09M
derived: sum of 2 quarters · filed 2018-11-09
-$71.17M
10-Q · filed 2018-11-09
-$71.81M
10-Q · filed 2017-11-09
-$90.26M
derived: sum of 4 quarters · filed 2019-03-01
2017-06-30-$24.59M
10-Q · filed 2018-08-09
-$24.69M
10-Q · filed 2017-08-09
-$45.67M
10-Q · filed 2018-08-09
-$45.67M
10-Q · filed 2017-08-09
-$64.76M
derived: sum of 3 quarters · filed 2019-03-01
-$82.29M
derived: sum of 4 quarters · filed 2019-03-01
2017-03-31-$21.08M
10-Q · filed 2018-05-09
-$20.98M
10-Q · filed 2017-05-10
-$40.17M
derived: sum of 2 quarters · filed 2019-03-01
-$57.70M
derived: sum of 3 quarters · filed 2019-03-01
-$69.24M
derived: sum of 4 quarters · filed 2019-03-01
2016-12-31-$19.09M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
-$36.62M
derived: sum of 2 quarters · filed 2019-03-01
-$48.16M
derived: sum of 3 quarters · filed 2019-03-01
-$55.99M
10-K · filed 2019-03-01
-$55.73M
10-K · filed 2017-03-16
2016-09-30-$17.53M
10-Q · filed 2017-11-09
-$29.07M
derived: sum of 2 quarters · filed 2017-11-09
-$36.90M
10-Q · filed 2017-11-09
-$44.01M
derived: sum of 4 quarters · filed 2018-03-12
2016-06-30-$11.54M
10-Q · filed 2017-08-09
-$19.38M
10-Q · filed 2017-08-09
-$26.48M
derived: sum of 3 quarters · filed 2018-03-12
-$31.41M
derived: sum of 4 quarters · filed 2018-03-12
2016-03-31-$7.84M
10-Q · filed 2017-05-10
-$14.94M
derived: sum of 2 quarters · filed 2018-03-12
-$19.86M
derived: sum of 3 quarters · filed 2018-03-12
-$23.56M
derived: sum of 4 quarters · filed 2018-03-12
2015-12-31-$7.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12
-$12.03M
derived: sum of 2 quarters · filed 2018-03-12
-$15.72M
derived: sum of 3 quarters · filed 2018-03-12
-$19.21M
10-K · filed 2018-03-12
2015-09-30-$4.93M
10-Q · filed 2016-11-09
-$8.62M
derived: sum of 2 quarters · filed 2016-11-09
-$12.11M
10-Q · filed 2016-11-09
-$13.90M
derived: sum of 4 quarters · filed 2017-03-16
2015-06-30-$3.69M
10-Q · filed 2016-08-15
-$7.19M
10-Q · filed 2016-08-15
-$8.97M
derived: sum of 3 quarters · filed 2017-03-16
-$10.38M
derived: sum of 4 quarters · filed 2017-03-16
2015-03-31-$3.49M
10-Q · filed 2016-05-16
-$5.28M
derived: sum of 2 quarters · filed 2017-03-16
-$6.69M
derived: sum of 3 quarters · filed 2017-03-16
2014-12-31-$1.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16
-$3.19M
derived: sum of 2 quarters · filed 2017-03-16
-$5.40M
10-K · filed 2017-03-16
2014-09-30-$1.41M
10-Q · filed 2015-12-17
-$3.62M
10-Q · filed 2015-12-17
2013-12-31-$3.18M
10-K · filed 2016-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
GERON CORP (GERN)United States$0.803B-12.14
Faeth Therapeutics, Inc. (FTH)United States$0.750B
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
COLLEGIUM PHARMACEUTICAL, INC (COLL)United States$0.737B24.57
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44